M ediator, containing multiple subunits, transduces regulatory information from enhancers to promoters to facilitate transcription factor binding and RNA polymerase II recruitment to the promoter of target genes.
1,2 MED1 (mediator subunit 1) often colocalizes or co-occupies with cell-type-specific master transcription factors and active histone markers at the enhancer/promoter region of the target genes. 3 In mammalian cells, MED1 was originally identified as a PPAR (peroxisome proliferator-activated receptor)-binding protein, which increases the transcriptional activity of PPARγ. 4 Subsequently, MED1 was found to also bind to the TRAP (thyroid hormone receptor-associated protein) complex and function as a coactivator for several other nuclear receptors, including retinoic acid receptor, RXR (retinoid x receptor), vitamin-D receptor, FXR (farnesoid X receptor), estrogen receptor, and glucocorticoid receptor. [4] [5] [6] Furthermore, MED1 regulates several transcription may have pivotal but distinct roles in various pathophysiological states depending on the tissue. The innate immune response and lipid retention in monocytes/macrophages are imperative in the initiation, progression, and exacerbation of atherosclerosis. 17, 18 Tissue macrophages have immense plasticity and can be classified into the classically activated proinflammatory M1 macrophages and alternatively activated anti-inflammatory M2 macrophages.
19 M1 macrophages show an elevated level of proinflammatory cytokines, including IL-1β(interleukin 1β), TNF-α (tumor necrosis factor α), and MCP-1 (monocyte chemoattractant protein 1). In contrast, anti-inflammatory M2 macrophages have various functions, including regulation of immunity, maintenance of tolerance, and tissue repair/wound healing. 20 PPARγ activation primes human monocytes into alternative M2 macrophages; thus, PPARγ transactivates anti-inflammatory genes such as IL-10 via its PPAR-responsive element (PPRE). 21, 22 PPARγ activation by 15d-PGJ2, a synthetic PPARγ ligand, upregulates several M2 markers such as Arg1 (arginase 1). 23 In addition, PPARγ suppresses the expression of proinflammatory genes by interacting with proinflammatory transcription factors such as AP-1, NFAT (nuclear factor of activated T cells), and NF-κB (nuclear factor-kappa B). 24, 25 In the context of atherosclerosis, apolipoprotein E (ApoE)-deficient (ApoE −/− ) mice receiving troglitazone, a PPARγ agonist, showed decreased atherosclerosis. 26 Furthermore, PPARγ deletion in macrophages increased atherosclerosis in mice with an LDLR (low-density lipoprotein receptor)-null (LDLR −/− ) background. 27 Because MED1 positively regulates PPARγ, which is antiatherosclerotic in macrophages, we hypothesized that MED1 is also involved in the development of atherosclerosis. For this purpose, we generated a mouse line with MED1 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MED1 Deficiency in Macrophages Increases Atherosclerosis
To investigate the role of MED1 in macrophages in atherosclerosis, we developed macrophage-specific MED1 knockout (MED1 Figure 1A ) and (9.7±0.8% versus 18.8±2.0%; Figure 1B ), for an increase of 54% and 93%, respectively. Atherosclerosis was also increased greatly in the aortic root of MED1 ; Figure 1C and 1D). Furthermore, TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining showed increased apoptosis in the aortic roots of MED1 ΔMac /ApoE −/− mice fed Western diet ( Figure II in the online-only Data Supplement). However, the lipid profile was comparable between the 2 groups of mice under either diet (Tables I and II in the online-only Data Supplement) . These results suggest that MED1 silencing in a monocytic lineage is sufficient to exacerbate both spontaneous and dietinduced atherosclerosis. Figure 2A ). In addition, the level of NLRP3 (NLR family pyrin domain-containing 3) was increased, so NLRP3 inflammasome might be induced in the aorta of MED1
MED1 Deficiency Promotes Macrophage M1 Polarization
ΔMac / ApoE −/− mice. In contrast, the level of M2 marker genes, including Arg1, Mrc1 (mannose receptor C type 1), Retnla/ Fizz1 (resistin-like α), Chi3l3 (chitinase 3-like 3), and PPARγ, was lower in aortic tissue of MED1 ΔMac /ApoE −/− mice showed augmented mRNA expression of IL-1β, IL-6, COX2, iNOS, Gro1, TNFα, NLRP3, VCAM-1 (vascular cell adhesion molecular 1), and ICAM-1 (intercellular adhesion molecule 1; Figure 3A ). However, the mRNA expression of M2 marker genes (eg, Arg1, Mrc1, Retnla, and Chi3l3), PPARγ, and IL-10 was significantly reduced in MED1 PMs. Compared with Ad-null overexpression, Ad-MED1 overexpression decreased the mRNA levels of IL-1β, IL-6, COX2, iNOS, and TNFα in wild-type PMs ( Figure 3E ) but increased the expression of Mrc1, Chi3l3, and PPARγ M2 marker genes ( Figure 3F ). Figure 4B ). With comparable lipid profiles in the 2 groups of animals (Table III in 
MED1 Deficiency in Macrophages Increases
MED1 Deficiency in Macrophages Potentiates Innate Immune Stimulation
With results from animal experiments in Figures 1 through 4 suggesting the atheroprotective role of MED1 in macrophages, we then investigated the involved mechanism. First, we performed quantitative reverse transcription-polymerase chain reaction analysis for MED1 expression in PMs after stimulation with lipopolysaccharide (LPS), an innate immune stimulation that is well known to induce M1 polarization. The expression of MED1 and PPARγ was strongly repressed by LPS treatment ( Figure  IV in the online-only Data Supplement). 30 Next, the differential gene expression in MED1
fl/fl and MED1 ΔMac PMs stimulated with or without LPS was analyzed using mouse atherosclerosis PCR array. The heat map in Figure 5A reveals that the expression of 20 genes involved in innate immune response and M1 polarization was significantly higher in MED1
ΔMac than in MED1 fl/fl macrophages after LPS treatment. Upregulated genes in MED1
ΔMac macrophages were the proinflammatory genes MCP-1, chemokine (C-C motif) ligand 5 (CCL5), Gro1, IFNγ, IL-1α, IL-1β, and TNFα; adhesion molecules CD44, ICAM-1, ITGA2 (integrin subunit α2), THBS4 (thrombospondin 4), and VCAM-1; apoptosis-related genes BCL2A1α (BCL2-related protein A1α), CASP8 (caspase-8), and CFLAR (FADD-like apoptosis regulator), and TNFαIP3, also known as A20 (TNFα-induced protein 3); and extracellular molecules, including LIF (leukemia inhibitory factor), PDGFB, SERPINB2 (serpin family B member 2 ), SERPINE1 (serpin family E member 1), and TNC (tenascin C). Conversely, downregulated genes were PPARγ, RXRα, and BCL2, and BCL2L1 (Bcl-2-like 1) antiapoptosis genes. Using quantitative RT-PCR, we further validated the mRNA expression of M1 marker genes in MED1 fl/fl and MED1
ΔMac macrophages challenged with LPS. Levels of M1 markers, including IL-1β, IL-6, COX2, MCP-1, iNOS, Gro1, TNFα, NLRP3, VCAM-1, ICAM-1, and CCL5, were confirmed to be higher in LPS-treated MED1
ΔMac than in MED1
fl/fl macrophages ( Figure 5B ). The protein levels of these inflammatory markers, such as COX2, MCP-1, iNOS, and TNFα, were consistently increased in MED1 ΔMac macrophages treated with LPS ( Figure 5C) . Cytoscape software was then used to construct an MED1-related gene regulatory network that consolidated the results in Figure 5A and 5B. Such in silico analysis shown in Figure 5D demonstrated that MED1 deficiency downregulated PPARγ and concurrently upregulated molecules facilitating a /ApoE −/− macrophages set to 1. In C-F, the Ad-null-infected levels were set to 1. Data are mean±SEM from 3 independent experiments. *P<0.01.
proinflammatory and dysregulated redox state, which potentiated the phenotype switch from M2 to M1 macrophages. The proinflammatory nature of MED1
ΔMac PMs is also supported by the nuclear portion of p65 NF-κB being slightly increased in MED1
ΔMac PMs and the C/EBPβ mRNA level increased in LPSstimulated MED1
ΔMac PMs ( Figure V in the online-only Data Supplement).
PPARγ Induction of M2 Marker Genes Depends on MED1
Because PPARγ is required for the maturation of M2 macrophages and MED1 is essential for PPARγ-regulated transactivation, 12,13,31 we then studied how MED1 is involved in the PPARγ-mediated M2 phenotype switch. We first used ChIP (chromatin immunoprecipitation) assay to examine the effect of MED1 on the binding of PPARγ to the PPRE in the promoter region of M2 marker genes including PPARγ, Arg1, Mrc1, and Chi3l3 ( Figure 6A ). PGC1α lacking the PPRE in the promoter was used as positive control ( Figure We then investigated whether the agonist-enhanced PPARγ activity depends on MED1 by transfecting RAW264.7 cells with PPRE-TK-luc reporter constructs together with control or MED1 siRNA. The transfected cells were then stimulated with PPARγ agonist rosiglitazone. As shown in Figure 6C , rosiglitazone treatment significantly induced the PPRE-driven transcriptional activity in RAW264.7 cells transfected with control siRNA. However, this induction was attenuated in cells with MED1 knocked down. In line with this result, rosiglitazone treatment increased the expression of the PPARγ-regulated genes, including CD36, ABCA1, and ABCG1 in MED1 fl/fl , when compared with MED1
ΔMac macrophages ( Figure 6D ).
Transcriptional activation is associated with a euchromatin state in the promoter and enhancer regions. Indeed, macrophage-unique PPARγ binding sites in the genome coincide with the active histone marker H3K9ac. 32 Accordingly, we used ChIP-quantitative RT-PCR assay to investigate whether MED1 regulates the expression of M2 genes by modulating the chromatin states at the promoter or enhancer region of the M2 marker genes. Nuclear extracts were immunoprecipitated first with antibodies for H3K4me1 (recognizing both active enhancers and promoters) and H3K27ac (recognizing active enhancers). With PPARγ and Arg1 as representative M2 marker genes, we profiled the promoter and enhancer regions of these genes defined in ENCODE data ( Figure 6E) . Primer sets were then designed for quantitative RT-PCR assessment of the enrichment of H3K4me1 and H3K27ac in these upstream regions. Compared with control RAW264.7 cells, MED1 knockdown significantly reduced the enrichment of H3K4me1 at both promoter and enhancer regions, whereas H3K27ac was less abundant in the enhancer region of PPARγ and Arg1 ( Figure 6F ).
IL-4 induces activation of alternative M2 macrophages with attendant increase in the expression of PPARγ and other prototypical target genes that characterize the M2 phenotype. 20 To further explore the role of MED1 in PPARγ-dependent M2 transition, we compared the mRNA level of M2 marker genes in MED1 fl/fl and MED1 ΔMac macrophages with or without IL-4 stimulation. At the basal level (without IL-4 treatment), the expression of M2 markers, including PPARγ, Arg1, and Chi3l3, was comparable between MED1
ΔMac and MED1 fl/fl macrophages, whereas Mrc1 expression was lower in MED1
ΔMac macrophages ( Figure 7A ). With IL-4 treatment, the expression of these M2 markers was strongly induced in MED1 fl/fl macrophages. However, such IL-4 induction of M2 . After a 6-wk chow diet then 12-wk Western diet, recipient mice were killed. Atherosclerotic lesion areas in the aorta tree (A) and aortic roots (B) were analyzed, and data are presented as mean±SEM. *P<0.05.
genes was significantly attenuated in MED1
ΔMac macrophages ( Figure 7A ). The decreased expression of M2 markers was also recapitulated in RAW264. 
Discussion
The principal finding of this study is that MED1 in macrophages is essential for an atheroprotective phenotype, which is mainly supported by the increased atherosclerosis in ApoE −/− or LDLR −/− mice with MED1 deficiency in bone marrowderived macrophages. These results reveal a new function for MED1 in macrophages in addition to its roles in lipogenesis in liver and insulin sensitivity in muscle. The underlying mechanism is that MED1, functioning as a transcriptional coactivator, is essential for the PPARγ-mediated M2 polarization. Previous study by Odegaard et al 31 indicated that PPARγ preferentially binds to the PPRE located at the promoter region of M2 marker genes (eg, Arg1). Our results further demonstrate that such transactivation of PPARγ on M2 marker genes depends on MED1 serving as a coactivator (summarized in Figure 7E ).
Given that PPARγ is a master transcription factor for the monocytic lineage, MED1 may be an integrated part of the PPARγ transcriptional machinery in macrophages. However, MED1 also participates in the transcriptional activation regulated by several proinflammatory transcription factors such as NF-κB and C/EBPβ. 9, 33 Although MED1 in macrophages facilitates PPARγ-mediated M2 gene expression, this positive effect seems to be omitted in regulating proinflammatory genes, including M1 markers that are regulated by NF-κB and C/EBPβ. About possible MED1, acting as a superenhancer, may change the euchromatin status of M2 genes via histone modification and enhancer activity, which also depends on the expression level or activity of lineage-dependent transcription factors such as PPARγ in macrophages. 34 Although MED1 is ubiquitously expressed, tissue-related functions depend on the MED1-enhanced expression of genes regulated by tissue-related master transcription factors. 3 Hence, MED1 interacting with PPARγ to maintain an optimal level of M2 genes is essential to maintain macrophage homeostasis. Conversely, MED1 deficiency in macrophages would lead to impaired maturation of PPARγ-driven M2 macrophages. Data presented in Figure 7C showed that M2 stimuli (eg, IL-4) increased the level of MED1 and PPARγ in RAW264.7 cells. On the contrary, M1 stimuli (eg, LPS) suppressed the expression of MED1 and PPARγ in macrophages ( Figure IV in the online-only Data Supplement). 30 Thus, it is reasonable to infer that the abundance of the MED1/PPARγ complex contributes to M1 versus M2 polarization. In terms of atherosclerosis, an optimal level of MED1 in monocytes/macrophages would be atheroprotective. This postulation is supported by an increase in the M1-like macrophages in the early stage of atherosclerosis in MED1
ΔMac /ApoE −/− mice ( Figure III in the online-only Data Supplement).
MED1 also seems to regulate SDTF (signal-dependent transcription factor)-dependent expression. 35 In accordance with the concept of SDTFs, PPARγ induced by IL-4 ( Figure 7E ) can be considered SDTF-dependent regulation during the M2 polarization. In the context of epigenetic regulation, the IL-4 induction of PPARγ level seems to increase PPARγ binding to the PPRE at the upstream region of various M2 genes. 20 Thus, the enhanced atherosclerosis in MED1
ΔMac /ApoE −/− mice ( Figure 1 ) would be mainly because of the impaired MED1/PPARγ regulation of M2 polarization in monocytes/macrophages. Intriguingly, MED1 deficiency in mouse liver causes hypercholesterolemia (J. Borensztajn and J.K. Reddy, unpublished results, 2010) and therefore MED1 would regulate cholesterol metabolism in hepatocytes, which in turn affects the lipoprotein profile in the circulation. In the current study, lipid profiles were comparable between MED1
ΔMac /ApoE −/− mice and their MED1 fl/fl /ApoE −/− littermates under a chow diet or atherogenic Western diet (Tables  I and II in Given the technical limitations in our analysis of cellular cholesterol content, a contribution of cellular cholesterol and lipid raft cholesterol to changes in macrophage signaling and M1/M2 phenotypic change should not be excluded.
Besides PPARγ, MED1 can interact with many other nuclear receptors, some of which have been shown to exert anti-inflammatory effects in macrophages. 37 Using bioinformatics, we found that the promoter regions of the M2 genes (eg, PPARγ, Arg1, Mrc1, and Chi3l3) do include the putative binding sites for RXRα, RARα, RORα, FXR, and HNF4α ( Figure XIIA in the online-only Data Supplement). Similar approach has been used to infer the binding sites of NF-κB, C/EBPβ, RXRα, RARα, RORα, FXR, and HNF4α in the promoters of M1 marker genes (eg, COX2, iNOS, and TNF; Figure XIIB in the online-only Data Supplement). This in silico analysis suggests that these nuclear receptors may also be involved in the anti-inflammatory effect exerted by MED1 in macrophages.
Superenhancers were originally defined by the differential level of MED1 enrichment at multiple loci in the genome. MED1 interacting with BRD4, an epigenetic reader that recognizes acetylated lysines, is involved in the inflammatory response in myeloma tumor cells. 38 Inhibition of BRD4 by the thienotriazolodiazepine JQ1 reduces the MED1 enrichment, especially in the superenhancer regions.
38 JQ1 also attenuates TNFα-induced NF-κB activation in endothelial cells, thereby decreasing atherosclerosis. 39 This observation may seem contradictory to our finding that MED1 deficiency was pro-M1, or proatherosclerotic, whereas suppression of MED1 binding to enhancers by JQ1 is antiatherosclerotic. 3, 39 A multitude of explanations may rationalize such paradox. First, our experimental approaches involved tissue-specific MED1 ablation in macrophages, whereas in the previous study, BRD4 inhibition decreased MED1 superenhancer binding in endothelial cells. These differential results in macrophages versus endothelial cells agree with the notion that MED1-modulated gene expression is tissue dependent. Nonetheless, the paradox is that neither study can justify why only a certain set of genes can be transcriptionally activated, given that MED1 is ubiquitously important in the Mediator complex. Thus, pro-and anti-inflammatory stimulating cues combined with tissue-specific signals may cause a unique recruitment of pioneer transcription factors, coactivators, and cosuppressors to the MED1-associated Mediator complex so that a set of genes are selectively activated. An alternative explanation is that distinct signals may result in conformational changes of MED1, which in turn affect the genomic loci of MED1 superenhancer binding that may direct long-distance chromatin remodeling and ensuing gene expression.
In summary, our data strongly support that MED1 in macrophages is antiatherosclerotic because of PPARγ-dependent M2 polarization. However, the detailed molecular insights of the selective induction of M2 marker genes require further
